Article
Immunology
Chihiro Ishiwatari-Ogata, Masanao Kyuuma, Hitoshi Ogata, Machi Yamakawa, Katsuya Iwata, Motoki Ochi, Miyuki Hori, Noriyuki Miyata, Yasuyuki Fujii
Summary: In this study, we found that ozoralizumab is a promising treatment for rheumatoid arthritis, with low immunogenicity and superior efficacy in secondary failure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Anne Montfort, Florie Bertrand, Julia Rochotte, Julia Gilhodes, Thomas Filleron, Jean Milhes, Carine Dufau, Caroline Imbert, Joelle Riond, Marie Tosolini, Christopher J. Clarke, Florent Dufour, Andrei A. Constantinescu, Nilton De Franca Junior, Virginie Garcia, Michel Record, Pierre Cordelier, Pierre Brousset, Philippe Rochaix, Sandrine Silvente-Poirot, Nicole Therville, Nathalie Andrieu-Abadie, Thierry Levade, Yusuf A. Hannun, Herve Benoist, Nicolas Meyer, Olivier Micheau, Celine Colacios, Bruno Segui
Summary: Dysregulation of lipid metabolism affects cancer cell behavior, and increasing SMPD3 expression can reduce melanoma growth and enhance Th1 polarization and CD8(+) T-cell-dependent immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Henri Chedotal, Dilip Narayanan, Katrine Povlsen, Charlotte H. Gotfredsen, Roberta Brambilla, Michael Gajhede, Anders Bach, Mads H. Clausen
Summary: Tumor necrosis factor (TNF) is a pleiotropic cytokine involved in immune system homeostasis and various diseases. Biologics targeting TNF have limitations, and therefore, small molecules and alternative strategies for modulating TNF signaling are being explored.
DRUG DISCOVERY TODAY
(2023)
Review
Immunology
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu, Zhen Sun
Summary: "Seven biosimilars of adalimumab approved for rheumatoid arthritis treatment by FDA and/or EMA have shown similar efficacy, safety, and immunogenicity to adalimumab, with switching trials indicating no significant impact on these factors."
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kunio Asonuma, Keiji Ozeki, Hajime Yamazaki, Shinji Okabayashi, Soh Okano, Ryo Ozaki, Nobuaki Nishimata, Hiroki Kiyohara, Naoki Ichinari, Taku Kobayashi, Masahiro Yamada, Mao Matsubayashi, Yoko Yokoyama, Shoko Arimitsu, Junji Umeno, Yoshinori Munetomo, Akira Andoh, Shinichiro Shinzaki, IBD Terakoya Grp
Summary: The use of immunomodulators after discontinuing anti-TNF-alpha antibody treatment was not significantly associated with relapse in patients with UC. Careful patient follow-up is necessary when discontinuing due to side effects or in younger patients at the time of discontinuation.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Eva Vargas, Fangyu Zhang, Amira Ben Hassine, Victor Ruiz-Valdepenas Montiel, Rodolfo Mundaca-Uribe, Ponnusamy Nandhakumar, Putian He, Zhongyuan Guo, Zhidong Zhou, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang, Joseph Wang
Summary: This study presents a unique design of bioelectronic affinity sensors using natural cell membranes as recognition layers for protein detection and prevention of biofouling. By coating electrochemical transducers with human macrophage membrane as the capture layer and human red blood cell membrane as the nonspecific binding prevention layer, the sensor demonstrates a remarkable limit of detection for tumor necrosis factor alpha (TNF-alpha) cytokine. The integration of natural cell membranes and electronic transduction offers synergistic functionalities for a broad range of biosensing applications.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Article
Oncology
Ping Li, Fengyang Chen, Jingbin Zheng, Yang Yang, Yuan Li, Yifei Wang, Xin Chen
Summary: Cyclophosphamide can abrogate the effects of bleomycin on the expansion of Tregs, and the combination therapy of these two chemotherapeutic agents shows synergistic anti-tumor effects in cancer treatment.
CANCER BIOLOGY & MEDICINE
(2021)
Article
Cell Biology
Qiang-Wei Wang, Wei-Wei Lin, Yong-Jian Zhu
Summary: This study integrated and analyzed the expression patterns and clinical significance of TNF family-related genes in gliomas. It was found that the expression of most TNF family members was positively correlated and most were related to the overall survival of patients. A TNF family-based signature was developed and shown to be an independent prognostic marker for glioma patients.
CELL COMMUNICATION AND SIGNALING
(2022)
Review
Biochemistry & Molecular Biology
Andy Ruiz, Yadira Palacios, Irene Garcia, Leslie Chavez-Galan
Summary: Tumor necrosis factor (TNF) is a key cytokine regulating inflammatory responses and plays a crucial role in granuloma formation during mycobacterial infections. The interactions between soluble and transmembrane TNF with their receptors influence effector mechanisms, providing insights into potential therapeutic strategies against mycobacterial infections. Understanding the structural and activation pathways of TNF and its receptors can offer valuable knowledge for developing more efficient therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biotechnology & Applied Microbiology
Xinmei Liao, Hui Liang, Jian Pan, Qian Zhang, Jiaqi Niu, Cuili Xue, Jian Ni, Daxiang Cui
Summary: A high-affinity, fully human anti-TNF alpha antibody named Haidalimumab was developed in this study, showing comparable TNF alpha binding affinity to Humira. Haidalimumab effectively neutralized rhTNF alpha toxicity and exhibited significant therapeutic effects in mouse models, suggesting potential therapeutic applications in rheumatoid arthritis or other autoimmune diseases.
Article
Rheumatology
Yoichi Nakayama, Ryu Watanabe, Kosaku Murakami, Koichi Murata, Masao Tanaka, Hiromu Ito, Wataru Yamamoto, Kosuke Ebina, Kenichiro Hata, Yuri Hiramatsu, Masaki Katayama, Yonsu Son, Hideki Amuro, Kengo Akashi, Akira Onishi, Ryota Hara, Keiichi Yamamoto, Koichiro Ohmura, Shuichi Matsuda, Akio Morinobu, Motomu Hashimoto
Summary: This study aimed to investigate whether TNFi without Fc is more effective than TNFi with Fc in RA patients with high RF titres. The results showed that RA patients with high RF titres who received TNFi without Fc had a significantly lower disease activity score than those treated with TNFi with Fc.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Cell Biology
Nadine Biesemann, Daniel Margerie, Christian Asbrand, Markus Rehberg, Virginia Savova, Inoncent Agueusop, Daniel Klemmer, Danping Ding-Pfennigdorff, Uwe Schwahn, Markus Dudek, Karen Heyninck, Evelyn De Tavernier, Sigrid Cornelis, Markus Kohlmann, Frank O. Nestle, Matthias Herrmann
Summary: The study found that inhibiting both TNF and IL-6 is effective in treating rheumatoid arthritis (RA). Single-cell RNA sequencing of RA patients revealed the synergistic effect of TNF and IL-6 on disease mechanisms and biomarkers. In mouse models, combining anti-TNF and anti-IL-6 antibodies resulted in sustained remission, improved histology, and effects on bone remodeling pathways.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Masahiro Iizuka, Takeshi Etou, Shiho Sagara
Summary: This article summarized the use of cytapheresis (CAP) in patients with refractory ulcerative colitis (UC) and discussed its advantages and limitations. The results showed that CAP had similar efficacy in patients with inadequate response to thiopurines or immunomodulators, but limited benefit in patients refractory to biologic therapies. Combination therapy with CAP and biologics could induce clinical remission in over 40% of patients with refractory UC. Extensive prospective studies are needed to understand the efficacy of this combination therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Immunology
Hongping Ba, Rui Jiang, Meng Zhang, Bingjiao Yin, Jing Wang, Zhuoya Li, Baihua Li, Xiaoxi Zhou
Summary: The research shows that tmTNF-alpha may play a critical role in malignant transformation and anti-inflammatory processes in colitis-associated cancer. Interventions targeting tmTNF-alpha expression and shedding could partially suppress inflammation and adenoma formation, suggesting potential therapeutic value in blocking the pathological process.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ping Li, Yang Yang, Xinyu Yang, Yifei Wang, Chon-Kit Chou, Mengmeng Jiang, Jingbin Zheng, Fengyang Chen, Xin Chen
Summary: The study found that TNF receptor type II (TNFR2) is expressed in a wide range of tumor cells. Knocking out TNFR2 in mouse colon cancer cells MC38 and CT26 using CRISPR/Cas9 technology inhibited in vitro proliferation and colony formation of cancer cells through inhibition of AKT phosphorylation and promotion of autophagy-induced cell death. In addition, TNFR2 deficiency significantly impaired the in vivo growth of MC38 or CT26 tumors in mice, accompanied by a decrease in soluble TNFR2 levels in the circulation and an increase in the number of tumor-infiltrating IFN gamma+ CD8 cells.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)